Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease

NCT03257046 PHASE1, PHASE2 COMPLETED

This is a Phase I/II randomized, double-blind, placebo-controlled, multiple rising dose study in patients with stable idiopathic Parkinson's disease (PD) to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ITI-214.

Details

Lead sponsor	Intra-Cellular Therapies, Inc.
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	40
Start date	Thu Sep 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Sep 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Parkinson Disease

Interventions

• ITI-214
• Placebo

Countries

United States